The relevance of our findings is amplified by the fact that several drugs approved by US Food and Drug Administration (FDA) and European Medicine Agency (EMA) targeting the JAK–STAT pathway are already available for the treatment of different forms of leukemia and lymphoma. This evidence concerns the gene SOAT1 and lymphoma.